ArticleJournal of ethnopharmacology2025
Açaí extract and anticancer drug combination promotes synergistic toxicity and apoptosis in MCF-10A cells of breast cancer model.
Article in Journal of ethnopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bibliometric Insights and Recent Advances in the Science, Technology, and Sustainability of Açaí (Foods (Basel, Switzerland) · 2026Review
- Shu Gan Jie Yu herbal combination enhances tamoxifen sensitivity in breast cancer cells via modulation of the SNCG/Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aim of the studyTo evaluate the toxicological potential between açaí extracts and two widely used anticancer drugs - methotrexate and tamoxifen. MATERIALS AND
methodsEuterpe oleracea Mart. fruit powder extracts obtained from a name brand company in Brazil and two açaí dietary supplement brands were tested on two cancer cell lines, MCF-7 and MDA-MB-231, and one normal epithelial breast cell line, MCF-10A. Cell viability was measured using MTT assay. The data was analyzed using SynergyFinder Plus and Compusyn to determine the potential synergism, antagonism, or additive effect of the açaí extract when combined with the selected anticancer drugs, tamoxifen and methotrexate.
resultsWhen combined with methotrexate, the methanol extract of the açaí powder and the acidic methanol extract of the açaí dietary supplements caused significant synergy (potentiation), thus increasing toxicity, of the combination to the normal cell line, MCF-10A. The combination of the acidic methanol extract of the açaí dietary supplements also induced apoptosis with the MCF-10A cells. Methotrexate was potentiated by the aqueous extract of the açaí powder when tested with the MCF-7 cells. Tamoxifen toxicity was increased only with the MCF-7 cells. Pre-exposure of the MCF-10A cells to the methanol extract of the açaí powder caused increased tamoxifen toxicity for the normal cell line but decreased toxicity for methotrexate combination. There were no significant indications of the açaí extracts causing an antagonistic relationship with either anticancer drug.
conclusionThe açaí extracts evaluated here potentiated both anticancer drugs, increasing their toxicity for all cell lines with the most significant increase in toxicity occurring with normal cell line, MCF-10A. The toxicity was further confirmed to be through induction of apoptosis. This calls for further investigation of the chemical constituents of açaí that are the cause of the toxicity of the combination of anticancer drug and açaí extract.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.